Psychiatric Times

04/07/2026

Early MRS data show AL001 delivers lithium effects across the brain while sparing glutamate, hinting at better tolerability than lithium carbonate.

Early MRS data show AL001 delivers lithium effects across the brain while sparing glutamate, hinting at better tolerability than lithium carbonate.

04/06/2026

🥦 It's time to take a closer look at mood and food. Let's explore new developments coming out of the field of nutritional psychiatry.

An interview with Felice Jacka, OAM, PhD, on the rapidly developing field of nutritional psychiatry.

04/03/2026

Psychedelics for the treatment of depression: strong interventions that must be handled with the utmost care.

Psychedelics continue to show potential for treatment of depression, Eriksson shares. ...

04/02/2026

Oral brexanolone LPCN 1154 for the treatment of postpartum depression failed to meet the primary endpoint in a phase 3 placebo-controlled trial.

Lipocine's oral brexanolone (LPCN 1154) for the treatment of postpartum depression failed to meet the primary endpoint in a phase 3 placebo-controlled trial.

04/02/2026

Our April theme: Schizophrenia.

If you are interested in being featured in a future Special Report/print issue, submit to our content series! https://www.psychiatrictimes.com/view/presenting-our-april-2026-theme-schizophrenia

04/01/2026

Alkermes has announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared with placebo in adults with narcolepsy type 1 and narcolepsy type 2.

New initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy type 1 and type 2.

03/31/2026

A panel of experts presented new consensus recommendations focused on the screening, diagnosis, and treatment of tardive dyskinesia among older adults in long-term care settings.

A panel of experts presented new consensus recommendations focused on the screening, diagnosis, and treatment of tardive dyskinesia among older adults in long-term care settings.

03/30/2026

As the month comes to a close, let's take a look at all the recent psychopharmacology updates:

Check out the pipeline updates from March!

03/27/2026

GLP-1 medications may have problematic interactions with eating disorders. Learn more in our latest YouTube short:

GLP-1 medications may have problematic interactions with eating disorders, explains Perlman. See more for National Eating Disorder Awareness week at https://...

03/26/2026

Interim results from a phase 2 trial of tazbentetol for treatment of schizophrenia showed trends of improving positive and negative symptoms in patients via synaptic regeneration.

Tazbentetol interim results show improvement in schizophrenia symptoms.

03/26/2026

The ASAM has announced new youth substance use disorder criteria, promoting early intervention, family-focused care, integrated mental health, and updated levels of treatment. https://www.psychiatrictimes.com/view/asam-announces-new-standards-for-adolescent-substance-use-disorder-care

03/26/2026

Proactive ICU psychiatry reduces delirium, length of stay, and readmissions while advancing equity and value-based critical care.

In this CME article, learn how proactive ICU psychiatry reduces delirium, length of stay, and readmissions while advancing equity and value-based critical care.